B

Bright Angel Therapeutics

3 employees

Bright Angel Therapeutics is developing new drugs that can prevent or revert the emergence of antifungal resistance.

Basic info

Industry

biotechnology research

Sectors

Biotechnology

Date founded

2017

Funding rounds raised

B

Bright Angel Therapeutics raised undisclosed on December 3, 2019

Investors: MaRS Investment Accelerator Fund, Viva BioInnovator, adMare BioInnovations and Lumira Ventures

B

Bright Angel Therapeutics raised undisclosed on January 1, 2016

Investors: UTEST, University of Toronto

FAQ